First subject has been dosed in the first-in-man Phase 1 clinical study of SAB-142, the first fully-human anti-thymocyte immunoglobulin (ATG) SAB-142 directly and specifically targets multiple immune ...
SAB Therapeutics SABS shares are trading higher on Thursday after the company said it has been granted Fast Track designation from the FDA for SAB-176 influenza immunotherapy with high ...
SAB BIO, a clinical-stage biopharmaceutical company focused on developing immunotherapy for type 1 diabetes (T1D), announced its financial results for Q1 2025, highlighting substantial progress in its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results